Ascellna Life Science Group

Ascellna Life Science Group is a clinical-stage biotechnology company focused on the discovery and development of next-generation mRNA therapeutics and vaccines. The company utilizes its proprietary A-mRNA synthesis platform and A-LNP delivery technology to create highly potent and stable nucleic acid medicines. Ascellna's pipeline spans multiple therapeutic areas, including oncology, infectious diseases, and rare genetic disorders. With operations in both China and the United States, the company aims to address global health challenges through innovative RNA engineering. Their lead programs are currently advancing through early-stage clinical trials and IND-enabling studies.